Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Q&A
  • About Us
    • Our Coverage
    • Team

Isofol Medical

0.66 SEK

+0.23 %

Less than 1K followers

ISOFOL

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data

Income statement

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Isofol Medical

2019202020212022202320242025
Revenue37.122.412.80.7
growth-%-39.6 %-42.9 %-94.4 %
EBITDA-166.3-184.7-202.9-165.8-41.3-47.2-56.0
EBIT-167.8-186.5-204.5-167.5-41.7-47.2-56.0
Profit before taxes-161.6-189.0-200.3-159.8-37.1-43.5-54.2
Net income-161.6-189.0-200.3-159.8-37.1-43.5-54.2
EPS-2.51-1.57-1.09-0.87-0.20-0.24-0.25
Dividend0.000.000.000.000.000.000.00
Dividend ratio-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %

Profitability and return on capital

2019202020212022202320242025
EBITDA-%-497.7 %-905.4 %-1,295.5 %-5,737.5 %
EBIT-%-502.4 %-912.5 %-1,308.3 %-5,788.9 %
ROE-154.0 %-283.9 %-62.9 %-100.8 %-30.5 %-55.8 %-50.2 %
ROI-110.3 %-127.6 %-49.9 %-74.8 %-26.4 %-44.2 %-41.9 %
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.